Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
CNS Pharmocology
CNS Pharmocology UCLA
| Question | Answer |
|---|---|
| What physiologic effects of free radical molecules may result in damage or cell death? | peroxidation of lipids (p. 953) oxidative damage to DNA (p. 956) oxidation of LDL cholesterol (p. 956) - forms atherosclerotic plaque blood vessel injury (p. 198) |
| Name three drugs or vitamins that may reduce damage produced by free radicals. | Vitamin C Vitamin E Selegiline Gingko Biloba |
| Describe the possible sites of drug action on neurotransmission. | Modulate neurotransmitter release Modulate neurotransmitter clearance from the synaptic cleft Modulate effects of the neurotransmitter at the post-synaptic receptor |
| Name two neurochemical strategies for drug therapy in Parkinson’s disease. | Increase DA activity Decrease Ach activity |
| Which class of drug may be most useful in mild or early PD? | MAO-B inhibitors |
| MAO-B Inhibitors | selegiline and rasagiline |
| anticholinergic drugs | trihexyphenidyl bentztropine biperiden diphenhydramine |
| Dopamine agonists | ergot derivatives: bromocriptine, pergolide non-ergot derivatives: pramipesole, ropinirole, apomorphine |
| bromocriptine, pergolide | ergot derivatives, DA agonist for PD |
| pramipesole, ropinirole, apomorphine | Non-ergot derivatives, DA agonist for PD |
| carbidopa and entacapone | used together as a Levodopa (l-dopa) to decrease metabolism |
| Name another clinical use for the antimuscarinics trihexyphenidyl and benztropine | reduce tremor and possibly rigidity in PD |
| trihexyphenidyl and benztropine | antimuscarinic for PD |
| Describe the mechanism of action for levodopa and carbidopa. | inhibits decarboxylation of levodopa in the intestine & peripheral tissues, thereby making more levodopa available to the CNS cannot pass BBB, therefore, does not prevent the conversion of levodopa to dopamine by decarboxylases in the brain |
| L-dopa | ups DA enters brain via active transport system once in brain, drug undergoes uptake into the few dopaminergic nerve terminals that remain in the striatum then l-dopa converts to dopamine |
| Describe early and late adverse effects of levodopa. | Early:N/V, postural hypotension Late: Dyskinesias in 1st yr. Loss of effectiveness, dysrhthmias, psychosis |
| What are some strategies for dealing with loss of effectiveness in L-Dopa problems after 3-5 years of therapy? | ncrease total dosing or dose frequency Use sustained release formulations supplement with other PD medications Take a drug holiday |
Created by:
UCLAnurse
Popular Pharmacology sets